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Summary The murine monoclonal antibody (Mab) against human common epithelial ovarian carcinoma,
CF511, was generated by immunising mice with human fetal tissue extract from early first trimester, followed
by booster injection of an ovarian cancer cell line. Mab CF511 recognised the 600 kDa sialylated glycoprotein
as different from previously known tumour associated-marker antigens. Distribution of the Mab CF511-
recognised antigen (CF511 antigen) in various tissues and sera was investigated. In immunohistochemical
analysis, Mab CF511 reacted strongly with tumour cells of ovarian serous, clear cell, endometrioid and
undifferentiated carcinoma and partially with those of mucinous carcinoma. Mab CF511 also reacted with
breast carcinoma as well as lung carcinoma. In normal tissues, Mab CF511 cross-reacted with only five tissues,
namely lung, breast, thyroid gland, fallopian tube and uterus. Serum levels of CF511 antigen were tested by
ELISA inhibition using Mab CF511. This assay showed the circulating CF511 antigen levels to be elevated in
25 of 36 sera from patients with various clinical stages of common epithelial ovarian carcinoma compared to
three of 47 and three of Ill sera from patients with other benign gynaecological diseases, including ovarian
cysts, uterine fibroids with or without endometriosis and normal healthy subjects, respectively. For the relation
between antigen levels and clinical stages of common epithelial ovarian carcinoma, greater than 34.0% ELISA
inhibition was detected in 100% of patients with advanced stages (FIGO III and IV) compared with in 35.3%
with early stages (FIGO I and II) patients. While patients with breast carcinoma (100%) and lung carcinoma
(100%) also had elevated circulating CF511 antigen levels, patients with hepatoma, colorectal carcinoma and
gastric carcinoma had no detectable elevation ofantigen. Although the test showed a high degree ofspecificity,
the detection of an elevated CF511 antigen level would not be so helpful in distinguishing patients with
ovarian carcinoma from those with either breast carcinoma or lung carcinoma. These data suggest that CF511
antigen is a useful new ovarian tumour marker for diagnosis and management of the disease.
Despite recent advances in the therapy of ovarian malig-
nancy, ovarian carcinoma is the most lethal of all
gynaecological carcinomas. Because of an insidious disease
arising from a deep-seated organ, initial detection is often
delayed. The common epithelial ovarian carcinomas con-
stitute the vast majority of all ovarian cancers (Petterson,
1985).
A large number of monoclonal antibodies (Mabs) against
ovarian carcinoma have been produced using hybridoma
technology, mainly by immunising mice with cancer cell lines
or their extracts, in an attempt to identify tumour-specific or
tissue-specific markers (Sakakibara et al., 1988; Nakagawa et
al., 1987; Miotti et al., 1985, 1987; Mattes et al., 1984, 1987;
Tsuji et al., 1985; Tagliabue et al., 1985; Croghan et al., 1984;
Bhattacharya et al., 1982; Bast et al., 1981). As yet, however,
none of the antigens identified appears to be tumour-specific.
The expression of ovarian and other cancer associated
antigen(s) recognised by Mab(s) has been frequently detect-
able in normal tissues, especially in fetal tissues, by further
extensive screening procedures. In this sense, some cancer
associated antigens have been considered to be onco-
developmental and/or tissue differentiation antigens (Feizi,
1985; O'Brien et al., 1986).
Therefore, we have taken an alternative approach, i.e.
immunised mice with embryonal tissues from fetus in early
first trimester, given booster injections of an ovarian cancer
cell line. The aim was to obtain efficiently antibodies which
could react to both carcinoma and fetal cells. In this study
we report one Mab, CF511, obtained using this novel ap-
proach, some biological properties of the antigen (CF511
antigen) and percentage incidence of the CF511 antigen in
sera from ovarian carcinoma patients.
Materials and methods
Human tissues
Fresh normal and neoplastic adult tissues were obtained
either at the time of surgery or at autopsy. Fetal tissues from
around the tenth week of gestation were obtained during a
therapeutic abortion in accordance with the guidelines
(Ethicality of the limits to the use of organs from dead
fetuses and neonates in research) of the Japanese Society of
Obstetrics and Gynaecology.
Cell line
The human ovarian clear cell carcinoma cell line, HAC-2,
which was provided by Dr M. Nishita, Tsukuba University
school of Medicine, was maintained in vitro by conventional
methods. Recently an HAC-2 cell clone was able to replicate
continuously but slowly in a chemically defined, serum-free
medium supplemented with Na2SeO3 (Nakabayashi et al.,
1982). No CA125 antigen was produced by HAC-2 cells
under either set of culture conditions as determined by
radioimmunoassay.
Cell and tissue extracts
Solid tissues were minced separately with scissors into small
fragments and washed twice with 0.15 M NaCI solution. The
tissue fragments were then placed into 10 volumes of ice-cold
extraction buffer (10 mM Tris-HCI, pH 7.2, 0.15 M NaCI,
0.02% NaN3, 1 mM phenylmethylsulphonyl fluoride and
0.5% Nonidet P40) and homogenised with a Polytron
homogeniser for 3 min on ice. Confluent monolayers of cul-
tured cells were detacted by 0.02% EDTA in Dulbecco
PBS(-), washed and resuspended in 10 volumes of ice-cold
extraction buffer. The homogenates and cell suspension were
then sonicated for 1 min, incubated for 20 min on ice, and
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centrifuged at 23,000g for 20 min at 0°C. The supernatants
were kept frozen at - 80°C until use. The protein concentra-
tions of the extracts were determined by the method of
Lowry et al. (1951).
Production ofMabs
BALB/c male mice were immunised 4-weekly with intra-
peritoneal (i.p.) injections of 2 mg protein of fetal extract
emulsified in Freund's complete adjuvant. The extract was
prepared from the homogenate of fetal tissues (excised liver
and small intestine). Four weeks later the mice were given
booster i.p. injections of 5 x 10' HAC-2 cells. Three days
following the booster, the spleen cells from the immunised
mice were fused by 50% polyethylene glycol (Boehringer
Mannheim, FR Germany) with P3X63Ag8U-1 myeloma
cells. Resulting hybrids were selected in HAT medium.
Supernatants were initially screened for reactivity against
HAC-2 cells using cell-target enzyme-linked immunosorbent
assay (cell-ELISA). Target cell-coated plates were prepared
as follows. HAC-2 cells, 2-3 x 104 per well, were cultured in
tissue culture microplates (Corning no. 25860, USA) for 2-3
days to obtain a monolayer. Wells were gently washed once
with PBS and then fixed with 0.05% glutaraldehyde (Sigma,
USA) in PBS for 5 min at room temperature. For the satura-
tion of free aldehyde groups they were incubated for 30 min
with 1% bovine serum albumin (BSA, Sigma, USA) in 0.1 M
glycine in PBS. Wells were washed twice with PBS and plates
were incubated for 20 min with 0.3% (wt/vol) H202 in
methanol for blocking the activity of endogenous peroxidase.
Wells were blocked with Tris-buffered saline (TBS) contain-
ing 5% skimmed milk (Difco, USA) and 0.1% merthiolate
for 2 h at room temperature or overnight at 4°C. Plates were
washed twice with TBS containing 0.05% Tween 20 (T-TBS),
and 50yl of hybridoma culture supernatants were added and
incubated for 4 h at room temperature. The wells were
washed three times with T-TBS, followed by addition of
50 il horseradish peroxidase (HRP) labelled goat anti-mouse
immunoglobulin (Ig) conjugate (Cappel, USA) diluted
1/1,000 in 5% skimmed milk in TBS and further incubated
for 2 h at room temperature. After repeated five times
washing, 150 ttl of O-phenylenediamine as a substrate was
added and measured absorbence at 492 nm was determined
after 20 min of colour development with a microplate reader
(MPR A4 Toyo Soda, Japan). The hybridomas cloned by
limiting dilution, expanded in vitro and were grown as an
ascitic form in pristane-primed BALB/c mice. The spent
culture media and ascites fluid were used as the source of
antibody.
Immunoperoxidase staining
Formalin fixed and paraffin embedded materials of common
epithelial ovarian carcinomas and normal tissues were
dewaxed, rehydrated through graded alcohol and blocked
endogenous peroxidase by the conventional method by
immersion in 0.3% H202 in methanol for 20 min. After
washing in PBS, followed by treatment with normal horse
serum, either hybridoma supernatants or Mab (10ILgml-')
was incubated on each section for 60 min. The biotinylated
anti-mouse Ig horse antibody (Vector, USA) followed by
avidin-biotinylated HRP (Vector, USA) was applied for
30 min. Sections were incubated for a few minutes in peroxi-
dase substrate (3,3' diaminobenzidine 4 HCI, DAB) solution.
After being washed with distilled water, the sections were
counter-stained with haematoxylin.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDSPAGE) and immunoblotting
SDSPAGE was carried out by the discontinuous system of
Laemmli, using 7.5% acrylamide gels under reducing condi-
tions. Transfer of antigens to nitrocellulose paper was per-
formed according to the method of Towbin et al. (1979).
Immunoblotting analysis was performed with residual bind-
ing sites which were blocked by incubation of blotted nitro-
cellulose paper with 5% skimmed milk in TBS, incubated
with Mab CF511 culture supernatant at 4°C overnight, fol-
lowed by incubation with properly HRP-conjugated anti-
mouse Ig goat antibody (Cappel, USA) for 2 h at room
temperature. The peroxidase activity was detected by expos-
ing the membrane to 0.2mg ml-' of DAB, 0.01% H202 in
TBS for 10 min.
Gelfiltration
HPLC system (TSK gel G-3000SW, 7.5 mm x 60 cm, Toyo
Soda, Japan) was used. The column was equilibrated with
50 mM PB, pH 6.8, 0.25 M NaCl, at a flow rate of
0.43 ml min-'. The antigenic content in each fraction was
assayed by ELISA inhibition test.
ELISAfor binding assay (antigen coated ELISA)
In order to confirm the releasing ability of Mab-recognised
antigen to the medium, wells of the 96-well microtitre plate
(Immunoplate, Nunc, Denmark) were coated with 50 Jl of
spent culture medium from HAC-2 grown in serum free
medium (100gg ml-' protein, HACCM(-)), blocked with
5% skimmed milk in TBS for 1 h at room temperature and
then the antibody solution, HRP-labelled antibody and the
substrate were reacted for the cell-ELISA as described above.
ELISA inhibition test
Either spent culture medium of HAC-2 or sera were pre-
incubated with an equal volume of purified antibody solu-
tion. Aliquots were inoculated into a microtitre well
precoated with HACCM(-) for further incubation. To the
wells on the microtitre plate was then added HRP-conjugated
goat anti-mouse Ig (1/1,000 diluted with 5% skimmed milk-
TBS) followed by determination at 492 nm by the addition of
substrate as mentioned above. Results were expressed in
terms of percentage of inhibition of ELISA signal according
to the following equation: % inhibition of ELISA = [1 -
(test OD - control OD)/(maximum OD - control OD)]
x 100.
Purification ofMab CF511
Purification of Mab CF511 was performed by precipitation
with 50% ammonium sulphate and gel filtration chromato-
graphy using Sephacryl S-300 (2.5 x 60 cm, buffered with
TBS containing 0.02% NaN3, Pharmacia, Sweden), followed
by HPLC (TSK gel G-4000SW, 7.7 mm x 60 cm, buffered
with 50 mM PB, pH 6.8, 0.25 M NaCl, Toyo Soda, Japan).
Fractions determined by the Ouchterlony test to have reacted
with goat anti-mouse IgM (Cappel, USA) were collected and
used.
Human sera
Serum samples from patients were supplied by Jikei Univer-
sity hospital. Sera of healthy volunteers were obtained in our
laboratories and from Tokuyama Soda laboratories. The
samples were stored at - 80°C until use.
Enzyme and reagent treatment
All treatments for enzyme and reagent were performed in the
Eppendorf microtubes because the treated and digested frag-
ments released from the antigen molecule, with or without
maintaining the antigenicity, had to be carefully determined.
Each tube of 3 mg packed cells (approximately 5 x 105 cells),
which were detached from the culture dish by 0.02% EDTA
treatment, was treated with either enzymes or reagents. For
NaOH or NaIO4 treatment, packed cells were treated either
with 0.1 N NaOH and 2 M NaBH4 for 25 h at 37°C or 15 mM
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15 h at room temperature in dark. The cultures treated with
neuraminidase (0.1 U ml', Seikagaku Kogyo, Japan),
0.125% trypsin (Difco, USA) or proteinase K (1 mg ml-',
Boehringer Mannheim, FR Germany) were centrifused and
each supernatant and precipitate was subsequently diluted in
SDS containing PAGE sample buffer and boiled for 5 min at
100°C. Resulting samples were analysed by SDSPAGE and
immunoblotting as described above.
Cross-reactivity ofMab CFSI1 to well known tumour markers
To assess the immunological specificity of Mab CF51 1, cross-
reactivity of the recognised tumour-associated markers to
CF511 antigen were tested for dose-response inhibition
against the immune reaction between Mab CF51 1 and
CF511 antigen. The standard reagents included in the com-
mercially available immunoassay kits were used as a source
of CA 19-9, CA 125 and CA 15-3 (Centocor, USA), DU-
PAN-2 (Kyowa Medix, Japan), SLX (Ohtsuka assay Lab,
Japan) and CSLEX (SRL, Japan).
Type ofIg
The subclass of Mab was determined by the Ouchterlony test
with rabbit IgG against different mouse Ig subclasses (ICN,
UK).
Results
Establishment ofthe Mab CFSJJ and its reactivity
The supernatant solutions from the 682 wells containing
growing hybridomas were screened initially by cell-ELISA,
followed by antigen (HACCM(-)) coated-ELISA and finally
by immunohistochemical examination, and five hybridomas
were established and cloned. Of the five Mabs obtained by
this fusion, Mab CF511 (IgM, K) reacted most strongly with
tissue sections of ovarian carcinomas immunohistologically
as well as in the ELISA test and further examinations were
carried out. Results of an immunohistological screening
study of the reactivity of Mab CF511 are presented in Tables
I and II. Mab CF511 stained all common epithelial ovarian
carcinomas tested, except four with mucinous histologies,
with no apparent selectivity for either papillary or infiltrating
medullary types. The immunoreaction of Mab CF511 occur-
red at the cell membrane. In tested normal adult tissues, Mab
CF511 reacted only with five tissues: bronchial and alveolar
epithelia in the lung, epithelial cells of the mammary gland,
follicular lining cells of the thyroid gland, epithelial cells of
fallopian tube and a few glandular cells of the uterine
endometrium. The results obtained from immunohistological
analysis coincided fully with the reactivities of the Mab
CF511 with various tissue extracts using the method of
immunoblot analysis. The level of CF511 antigen in fetal
extract was extremely low and weak but a significant band
was found at a level of more than 100 times concentration of
the protein content in the extract (Figure 1).
Levels ofCFSJ1 antigen in patients' sera
ELISA inhibition test was initially carried out. First, quan-
titative absorption of Mab CF511 was performed. The ap-
propriate dilution of Mab was established in titring the
antibody against HACCM(-) using the antigen coated-
ELISA system. The dilution used in the absorption test was
1:10 (5,g ml-') and, by this test, the appropriate dilution of
patients' sera was found to be 1:3 (Figure 2). The 1:10
diluted Mab CF511 was adapted to ELISA, and 1:3 diluted
sera were treated for CF511 antigen levels by their ability to
inhibit this ELISA signal according to the result of pre-
incubation with the Mab CF51 1. Figure 3 shows the level of
ELISA inhibition produced by a total of 219 sera from
healthy volunteers, patients with common epithelial ovarian
carcinoma, other carcinomas and benign diseases. The results
Table I Immunohistochemical reactivity of Mab CF511 to
neoplasms
No. of specimens
stained/total Staining
Tissue testeda intensityb
Ovarian tumour 27/35
cystadenocarcinoma 27/31
serous 6/6 3 +
mucinous 4/8 +
clear cell 7/7 3 +
endometrioid 6/6 2 +
undifferentiated 4/4 3 +
granulosa theca cell tumour 0/2
yolk sac tumour 0/2
Lung carcinoma 3/3 3 +
Breast carcinoma 2/2 3 +
Colon carcinoma 0/2
Gastric carcinoma 0/4
Hepatoma 0/3
aSpecimens from unrelated donors. bMean staining intensity on a
scale of 0-3 +: -, no reactivity; +, weak reactivity; 2 +, moderate
reactivity; 3 +, strong reactivity.
Table II Immunohistochemical reactivity of Mab CF511 to normal
tissues
No. of specimens
stained/total Staining
Tissue tested intensity
Brain 0/1
Breast 1/4 +, epithelial cell
Oesophagus 0/2
Stomach 0/2
Lung 4/4 3 +, alveolar cell
bronchial cell
Trachea 0/4
Small intestine 0/2
Kidney 0/2
Urinary bladder 0/2 -
Colon 0/2
Liver 0/4
Gall bladder 0/2
Pancreas 0/2 -
Muscle 0/2 -
Spleen 0/2
Thyroid gland 3/3 +, follicular cell
Uterus 4/4 2 +, glandular cell
Ovary 0/4
Fallopian tube 2/4 +, epithelial cell
See Table I for key.
are expressed as a percentage of inhibition of the ELISA
signal obtained with a pooled normal human control sera.
The cut-off level was based on the observed range of inhibi-
tion (mean + 2 s.d., 34.0%) of reactivities using sera from
healthy individuals. Sixty-nine per cent (25/36) of sera from
patients with common epithelial ovarian carcinoma showed a
significant inhibition of ELISA signal compared to 0/2 sera
from malignant ovarian tumour arising from germ cell or sex
cord mesenchymal cell, 0/7 sera from benign ovarian tumour
(including six cases of ovarian cyst), 3/40 sera from uterine
fibroid (with or without endometriosis) and 3/111 sera from
healthy individuals. The relation between the CF511 antigen
levels and clinical stages was evaluated in 32 common
epithelial ovarian carcinoma patients who were accurately
diagnosed for clinical stage at operation. Values of more
than 34.0% ELISA inhibition were detected in 6/17 cases
(35.3%) with early stage (stage I, 16 cases; stage II, one case)
and in 15/15 cases (100%) with advanced stage (stage III, 13
cases; stage IV, two cases), suggesting an association between
antigen level and tumour burden. All sera from lung car-
cinoma and breast carcinoma patients also showed ELISA
inhibition but no ELISA inhibition was noted in sera from
patients with hepatoma or with gastric carcinoma (including
one case of Krukenberg tumour) or colorectal carcinoma.
Furthermore, the menstrual cycle and pregnancy had no
effect on circulating antigen levels (data not shown).956 K. OHKAWA et al.
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Figure I SDSPAGE and immunoblot analysis of the antigen recognised by Mab CF511 (fetal extract (10 mg protein ml') of a,
cell or tissue extract (0.1 mg protein ml-'); bl and c3, HAC-2 cells; b2, ovarian clear cellcarcinoma; b3, ovarian mucinous
carcinoma; b4, ovarian serous carcinoma; b5, ovarian undifferentiated carcinoma; b6, hepatoma; b7, colon carcinoma; b8, gastric
carcinoma; cl, thyroid gland; c2, lung; c4, kidney; c5, endometrium). (>), origin; Mol. wt, molecular weight; BPB, bromophenol
blue.
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Figure 2 a, Titration of Mab CF511 against HACCM(-) as antigen. Serial 10-fold dilutions of hybridoma culture supernatant with
(A) or without (O) pre-incubation with HACCM(-) were tested in triplicate against antigen coated ELISA as described in
Materials and methods. b, Quantitative absorption of Mab CF511 with two patients' sera with ovarian carcinoma (0, U) and with
sera from healthy volunteers (0, 0). Suitable diluted Mab were absorbed with serially diluted sera and 1% BSA in TBS as a
control. The residual antibody activity was determined in triplicate against HACCM(-) as antigen with antigen coated ELISA as
described in Materials and methods. Residual antibody activity (% of control) = [OD (Mab absorbed by sera)]/[OD (Mab
absorbed by 1% BSA in TBS)] x 100. For each assay, s.d. of the triplicate determinations were within the markers.
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Figure 3 Inhibition of Mab CF511 ELISA original by sera from
patients with various cancerous and benign diseases as well as
healthy volunteers. Positive/negative cut-off was determined by
preliminary tests of sera from healthy volunteers to establish a
normal range of inhibition as described in Materials and
methods. Results were expressed in terms of % of inhibition of
ELISA signal as the following equation: % inhibition of ELISA
[1- (test OD - control OD)/(maximum OD - control OD)]
x 100. Each point represents the mean of duplicate determin-
ations of different two assays.
Biochemicalproperties ofCF511 antigen
The elution profile of gel filtration analysis of the antigen
either in an extract of HAC-2 cells or in a HACCM(-) is
shown in Figure 4. More than 90% of the applied activity
was detected in fractions eluting just after the elution volume
of thyroglobulin (660 kDa). Figure I shows immunoblot
analysis of SDSPAGE at the reduced condition of various
antigen preparations stained with Mab CF51 1. By immuno-
blot analysis using cell extracts from common epithelial
ovarian carcinomas and from some normal tissues as well as
from HAC-2 cells, Mab CF511 stained one band of apparent
molecular weight in excess of 330 kDa, but Mab CF511 did
not stain the thyroglobulin under the same conditions (data
not shown).
Evidence that Mab CF511 reacted with a glycoprotein
antigen was derived from six different experiments (Figure 5,
Table III). Initially characterisation of the CF511 antigen
was performed by neuraminidase, trypsin and proteinase K
digestion. After enzyme digestions, as shown in Figure 5, the
reactive bands to antibody were not found in the lanes of the
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Figure 4 HPLC-gel filtration profile of HACCM(-). Fractions
were tested for absorbence at 280 nm for CF511 antigen by
ELISA inhibition as described in Materials and methods. 1, blue
dextran; 2, thyroglobulin; 3, amylase; 4, BSA; 5, carbonic anhy-
drase.
samples derived from supernatants but only in those from
precipitates (cell lystates). The results show that the binding
ability of Mab CF511 to the antigen was partially destroyed
by the treatment with neuraminidase. This result indicated
that the antigenic sites recognised by Mab CF511 would
contain sialic acid residues (Figure 5). The same result was
also demonstrated by antigen coated or cell-ELISA.
Pre-incubation of antigen for 1 h with neuraminidase
resulted in a 55% decrease in ELISA signal (Table III).
However, trypsin treatment considerably increased the bind-
ing capacity of the antibody to defined antigen, separated by
SDSPAGE, transblotted on the nitrocellulose paper; how-
ever, migration of the antigen into the gel markedly
broadened and resulting bands were separated into four
(Figure 5). In contrast, treatment with proteinase K reduced
the binding capacity of antibody to antigen on the nitrocel-
lulose paper. However, weak but significant bands were
noticeable. These findings suggested that some parts of the
protein molecule might play a role in maintaining
antigenicity. Since CF511 antigen was partially digested by
trypsin without loss of the antigenicity, lysyl and arginyl
bonds of peptide chains may not affect the antigenicity. The
CF511 antigen was quite sensitive to 0.1 N NaOH and 2 M
NaBH4 (Figure 5). Moreover, treatment with proteinase K,
0.1 N NaOH and 2 M NaBH4 failed to make detectably
smaller molecular weight antigenic species. These findings
may be because of inadequate transfer during the immuno-
blotting procedure of smaller fragments consisting mainly or
entirely of carbohydrate. The CF511 antigen reactivity
remained unchanged by heat treatment for 15min at 100°C
(Table III). By treatment with NaIO4, the immunoblotting
analysis showed that the detection of the antigen demon-
strated that CF511 binding to the antigen was not sensitive
but increasing by the treatment with NaIO4; however, migra-
tion of the antigen into the gel decreased after this treatment,
indicating that CF511 antigen contained carbohydrate chain
and changes its conformation without decreasing
antigenicity. After treatment with NaIO4, the antibody bind-
ing activity to antigen was also increased more than 70% of
control when assay was carried out by antigen coated or
cell-ELISA (Table III). Since mild periodate oxidation at
acidic pH has been shown to cleave carbohydrate vicinal
hydroxyl groups without altering the structure of the
polypeptide chains, the increased antibody binding upon
periodate oxidation suggests that Mab CF511 may bind to
the antigenic sites of peptide backbone rather than to that of
carbohydrate molecules on the sialylated glycoprotein
antigen.
Comparison ofCF511 antigen with other tumour markers
The reactivity of Mab CF511 was compared with those of
Mab OC 125 (Bast et al., 1981), DU-PAN-2 (Metzger et al.,
1984) and DF3 (Hayes et al., 1985), which recognised the
peptide antigen in part, the sialylated carbohydrate antigen,
as well as NS 19-9 (Koprowski et al., 1979), FH 6 (Fukushi
et al., 1984) and CSLEX1 (Fukushima et al., 1984), which
recognised the sialylated Lewisa, the sialylated Lewis'-i and
sialylated Lewisx, respectively. Mab CF511 (5, 2, 0.5 fgml-'1)
Table III Effect of chemical or enzyme treatment of antigen on
Mab CF51la binding activity
Residual antigen
Agent activity (%)
Chemicals
control
NaIO4 (15 mM, room temp 15 h)
heat (100 C, 15min)
100
170
104
Enzymes
control 100
neuraminidase (0.1 Uml', 37C, 1 h) 45
aData obtained from antigen coated- or cell-ELISA determination.
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Figure 5 CF511 antigen (HAC-2 cell) was treated with either enzymes or chemical reagents. After treatment of packed cells with
each reagent, resulting supernatants and precipitates were then subjected to SDSPAGE followed by immunoblotting with Mab
CF511 as described in Materials and methods. a, lane 1, PBS; 2, 0.125% trypsin (supernatant); 3, 0.125% trypsin (cell lysate); 4,
proteinase K (I mg ml-, supernatant); 5, proteinase K (cell lysate); 6, NaOH/NaBH4 (mixture of supernatant and cell lysate). b,
Cells in 10 mm acetate buffer pH 4.5 with (2) or without (1) 15 mm NaIO4. c, Cells in 10 mm acetate buffer, pH 6.5, 10 mm CaCl2
with (2, 2 h; 3, 1 h) or without (1) 0.1 mlL' neuraminidase.
was pre-incubated for 17 h at 4°C with each standard sub-
stance contained in each assay kit. Then each incubation
mixture was assayed with inhibition ELISA assay as well as
according to the presented usual manner mentioned in each
kit. As shown in Table IV, Mab CF511 did not react with
the standard substance of each assay kit and no remarkable
competitive inhibition to make the standard curve for each
assay system was observed (data not shown).
Discussion
Mab CF511 was raised by immunising mice with a tissue
extract from 9-10-week-old fetus. The antibody binds to a
600kDa glycoprotein antigen found in many common
epithelial ovarian carcinoma preparations as well as in the
sera of many ovarian carcinoma patients. The occurrence of
this antigen in patient sera has permitted the preparation of a
competitive inhibition assay of ELISA signal using Mab
CF51 1. The results of the ELISA inhibition of clinical speci-
mens in this study indicated that the circulating CF5 1I
antigen was elevated in the sera of approximately 70% of
patients with common epithelial ovarian carcinoma. It was
also apparent that the levels of the antigen in carcinoma
patients were higher than those in healthy individuals or
patients with benign diseases. Furthermore, higher antigen
levels were found in the sera from ovarian carcinoma patients
with advanced clinical stage (FIGO III and IV) than from
those with the early stages of I or II. These data suggest that
the circulating CF511 antigen levels may reflect the size of
the tumour burden in ovarian carcinoma patients. On the
other hand, elevated antigen levels were detected in sera from
all patients with lung carcinoma and with breast carcinoma
tested. These findings indicate that the detection of an
elevated CF511 antigen level will be less helpful in distin-
guishing patients with ovarian carcinoma from those with
either lung or breast carcinoma. The arbitarily chosen cut-off
values of > 34.0% ELISA inhibition (mean + 2s.d.) resulted
in a specificity of <3.8% false positive and a sensitivity of
>69.4% true positives. The results also demonstrate that
.1 ... &A-. --- B.,
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Table IV Cross-reactivity of Mab CF511 was screened with other
well recognised tumour marker antigens
% inhibition of ELISA in various
Mab CF511 concentrations (jAgml I)a
Tumour marker antigens 0.5 2.0 5.0
CAl9-9 0 0 0
CA15-3 0 0 0
CA125 0 0 0
DU-PAN-2 0 0 0
SLX 0 0 0
CSLEX 0 0 0
CF511 antigen 100 100 100
normal mouse serum 0 0 0
aMab CF511 diluted by 1% BSA in TBS was pre-incubated with
standard antigens, CA 19-9 (240 U ml-'), CA 15-3 (500 U ml-'),
CA125 (500 U ml l'), DU-PAN-2 (1000 U ml -'), SLX (360 U ml1')
and CSLEX (224 U ml-'), induced in the commercially available
immunoassay kits. CF511 antigen (HACCM(-)) and normal mouse
serum were used as negative and positive controls, respectively. Then
the incubation mixtures were further incubated in antigen-coated
microtitre wells and ELISA inhibition was estimated as described in
Materials and methods.
CF511 antigen levels are not significantly elevated in patients
with benign ovarian diseases or malignant ovarian tumours
derived from germ cell or from mesenchymal cells and
uterine fibroids with or without endometriosis. Similarly,
patients with gastric, hepatic and colorectal carcinomas had
no detectable elevation of circulating CF511 antigen. Thus,
although an increased level of circulating CF511 antigen has
been detected in certain other malignancies, the pattern of
specificity suggests that measuring CF511 antigen levels may
be useful for diagnosis of ovarian carcinoma and in terms of
monitoring clinical course of ovarian epithelial carcinoma.
The CF511 antigen is a high molecular weight glycoprotein
of 600 kDa. Enzymatic digestions or reagents treatments of
CF511 antigen revealed that the antigen was partially sen-
sitive to neuraminidase or proteinase K and quite sensitive to
alkaline-borohydride but was resistant to trypsin or heat.
Furthermore, periodate oxidation of the CF511 antigen
reduced the electrophoretic mobility of CF511 antigen, but
increased the reactivity against antibody in SDSPAGE-
immunoblotting analysis as well as antigen coated ELISA.
The increased antibody binding upon periodate oxidation
suggests that epitope itself may not involve carbohydrate but
involve exposed protein backbone which is revealed by the
treatment. Since neuraminidase treatment of the antigen is
able to reduce antibody binding, a contribution by the ter-
minal sialic acid to the epitope cannot be ruled out, that is,
the sialylated carbohydrate chain is not a direct component
of the antigenic determinant but responsible for maintaining
of its conformation. Furthermore, the finding of sensibility to
alkaline-borohydride treatment suggests the serine-,
threonine-type carbohydrate chains are also required for
maintaining antigenicity. The reduced mobility of CF511
antigen in SDSPAGE was noted not only in the
neuraminidase treatment but also in the periodate oxidation.
The former is mainly because of the abolition of the negative
charge by desialylation of the sialylated glycoprotein where
the high levels of sialic acid produce a significant negative
charge on the SDS-glycoprotein complex. This curious
phenomenon has been reported in other proteins, including
high molecular weight tumour-associated glycoproteins
(Gahmberg & Anderson, 1982; Johnson et al., 1986; Bray et
al., 1987). The latter is probably related to the conforma-
tional change of the antigen molecule due to cleavage of
carbohydrate vicinal groups without altering the backbone-
peptide chains (Sekine et al., 1985). These findings suggest
that the presence of several sialyl carbohydrate chains on a
peptide backbone is probably required for maintaining
CF511 antigenicity. However, it is difficult to ascertain the
exact molecular properties of CF511 antigen from the data
obtained from the treatment of non-purilfied antigen.
Purification of the antigen is currently under investigation.
Although may Mabs generated against ovarian carcinoma
have been described, the possibility for sero-diagnosis of
ovarian carcinoma is demonstrated in only one Mab reported
(Bast et al., 1981, 1983). The most useful marker for patients
with common epithelial ovarian carcinoma has been
developed as CA125, a glycoprotein of high molecular weight
(over 200 kDa) (O'Brien et al., 1986; Masuho et al., 1984;
Matsuoka et al., 1987) and probably in the range of
2-3 x 103 kDa by gel filtration determination (Davis et al.,
1986) in nature by Mab OC125 raised against ovarian cancer
cell line. The CA125 antigenic determinant was recognised as
periodate-, neuraminidase-resistant and protease-, heat-
sensitive. These data strongly suggest that the CA125
antigenic determinant is composed, at least in part, of con-
formationally dependent peptide and is different from those
of CF511 antigen. Bast et al. (1983) reported that elevated
CA125 antigen levels could be detected in serum of more
than 80% of patients with common epithelial ovarian car-
cinomas and that levels correlated with progression or regres-
sion of the diseases. However, CA125 has been found to be
expressed not only in epithelial ovarian neoplasms but also in
the derivatives of the coelomic epithelium, such as the
muellerian epithelium, the linging cells from the coelomic
cavity and lung tissues (O'Brien et al., 1986; Kabawat et al.,
1983; Masuho et al., 1984; Matsuoka et al., 1987; Nouwen et
al., 1986). Serum levels of CA125 are therefore increased in a
number of non-ovarian carcinoma patients including those
with lung carcinoma and in some benign chronic pathologies
(Nouwen et al., 1986; Niloff et al., 1984). In immunohisto-
logical analysis, CF511 antigen was present in common
epithelial ovarian carcinoma (serous (100%), clear cell
(100%), endometrioid (100%), and undifferentiated car-
cinoma (100%), mucinous (50%)) as well as in normal lung,
breast, fallopian tube, uterus and thyroid gland. Serum levels
of CF511 antigen are significantly elevated not only in
ovarian carcinoma patients but also in either breast car-
cinoma or lung carcinoma patients regardless of the histo-
logical patterns. In contrast, no remarkable elevation of
antigen levels was noted in patients with gastric carcinoma or
with hepatoma and colorectal carcinoma. Furthermore, the
incidence of false-positive reaction of CF511 antigen in
patients with endometriosis was very much lower (22%) than
that for the CA125 detection system (Niloff et al., 1984).
These results clearly indicate that CF511 antigen is distinct
from CA125 and may be a generally useful marker for
diagnosis and monitoring diseases in patients with common
epithelial carcinoma as well as lung cell carcinoma and breast
carcinoma.
It has been reported that some Mabs, originated against
carcinomas derived from other organs, also cross-reacted
with human ovarian carcinomas (Thor et al., 1986; Friedman
et al., 1986). The most useful serodiagnostic Mab among
these is known as DF3, and is prepared against a human
breast carcinoma (Hayes et al., 1985). However, two distinct
differences in molecular characteristics between CF511
antigen and DF3 antigen are noticeable. The circulating
CF511 antigen is highly detectable (10/10, 100%) in sera
from patients with lung carcinoma, regardless of histology,
whereas only 1/11 (9.1%) patients with lung carcinoma had
DF3 positively detectable antigen levels (Friedman et al.,
1986). Another obvious difference between CF511 antigen
and DF3 antigen is found in molecular weight determination
using SDSPAGE-immunoblot analysis and/or gel filtration.
DF3 identified a glycoprotein with a heterogenous molecular
weight ranging from 300 to 450 kDa (Friedman et al., 1986;
Hayes et al., 1985; Sekine et al., 1985), whereas Mab CF511
recognises a band corresponding to a molecular weight of
more than 600 kDa glycoprotein. Furthermore, by using
competitive inhibition assay, the Mab CF511 and some
antibodies against well characterised tumour marker antigens
(CA19-9, CA125, CA15-3, DU-PAN-2, SLX, CSLEX)
clearly react with different antigen epitope. These results
suggest that the CF511 antigen does not seem to be related
to previously characterised antigens.
Although Mab CF511 was prepared using fetal tissue ex-960 K. OHKAWA et al.
tract from early first trimester as an immunogen followed by
booster injection using human ovarian cancer cell line, HAC-2,
the raising antigen, is not specific for fetal tissues and ovarian
carcinomas, but is present on a few normal adult tissues and
their derived carcinomas. Additionally, the antigen contents
of various tissue extracts from normal adult are much higher
than in those from fetus, as determined by antigen coated-
ELISA as well as immunoblot analysis. Particularly, the
antigen content in lung tissue is the same as that of common
epithelial ovarian carcinoma. Despite the restricted distri-
bution in some organs from normal adult, CF511 antigen
circulates at significantly lower levels in normal individuals
than in patients with carcinoma. These results suggest that
the antigen is a normal tissue antigen that is anomalously
shed or secreted into the circulation of epithelial ovarian
carcinoma, lung carcinoma and breast carcinoma patients.
Although the initial purpose of obtaining a Mab directed
towards onco-developmental antigens was not accomplished
in this investigation, the strategy used here may be useful in
the generation of new antibodies againsts onco-
developmental antigens as well as cancer associated antigens.
Such antibodies may be useful as tumour markers.
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